+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
P

Actively Recruiting

Researchers are evaluating mechanical ventilation strategies and the timing of muscle relaxation in patients with moderate to severe Acute Respiratory Distress Syndrome ARDS. The study aims to test personalized approaches for setting Positive End-Expiratory Pressure PEEP based on lung recruitability and whether early use of neuromuscular blocking agents NMBAs during prone positioning improves survival compared to rescue use. This trial addresses the lack of specific treatments for ARDS and focuses on improving survival by optimizing ventilation methods. Participants will be assigned to different ventilation strategies routine care with minimal lung distension using low tidal volume and conservative PEEP, routine care with maximal lung recruitment adjusting tidal volume and PEEP to maintain safe plateau pressures, or a personalized PEEP strategy based on a PEEP responsiveness test. Additionally, the study compares early systematic use of NMBAs during prone positioning to rescue use. Two randomizations occur first for ventilation strategy and second for NMBA timing. During the study, participants will undergo mechanical ventilation with assigned strategies, and researchers will monitor oxygenation, respiratory parameters, organ function scores, and mortality over time. Assessments include arterial blood gases, tidal volumes, respiratory rates, and organ failure evaluations at multiple time points up to one year. The primary outcome is 28-day all-cause mortality. Safety and long-term outcomes such as disability, cognitive function, quality of life, and return to work status will also be evaluated throughout the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
29 locations
S

Actively Recruiting

Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.

Age: 18Years +All GendersPhase 3
42 locations
O

Actively Recruiting

Researchers are creating the largest possible real-life group of patients with Chronic Myeloid Leukemia CML to collect long-term follow-up data. This observational study aims to analyze epidemiological trends, identify patient subgroups based on treatment response, evaluate new medications used in everyday care, study treatment discontinuations, and assess the effects of evolving treatment recommendations. The study collects clinical and biological information from CML patients both prospectively and retrospectively starting from diagnosis. Data gathering continues throughout the long-term follow-up period, even after treatment has stopped. There are no specific drugs or interventions administered in this observational study it focuses on monitoring and recording real-world patient experiences and responses. Participants provide data throughout their disease course, which may be collected for up to 30 years or until death or last follow-up. Researchers evaluate multiple outcomes including molecular and cytogenetic responses, treatment efficacy and tolerance, prognosis scores at diagnosis, body measurements, and medical history related to CML. This extensive monitoring helps better understand CML progression and treatment in real-life settings.

All AgesAll Genders
14 locations
C

Actively Recruiting

Researchers are studying men over 40 years old with benign prostatic hyperplasia BPH who need surgery to improve urinary symptoms. The trial compares two types of prostate surgery a conventional endoscopic resection and a newer partial surgery that aims to preserve ejaculation function. This study explores whether the partial surgery can maintain ejaculation without reducing the relief of urinary symptoms, which is important because ejaculatory dysfunction often lowers quality of life after surgery. Participants are randomly assigned to one of two surgical groups. One group undergoes conventional endoscopic resection of the prostate, while the other receives a partial endoscopic resection that preserves the apex area near the veru montanum. The study is single-blinded, meaning patients do not know which surgery they receive. The main focus is on symptom improvement measured by the International Prostatic Symptom Score IPSS six months after surgery. During the study, men will have evaluations at 1, 3, 6, 12, and 36 months after surgery. These assessments include urinary symptoms, ejaculation and overall sexual life, urinary flow rates, and any surgery-related complications. The trial tracks these outcomes to understand the benefits and effects of each surgical method over time. Patients are expected to comply with scheduled visits and provide informed consent before participating.

Age: 40Years +MALEPhase Not Applicable
17 locations
E

Actively Recruiting

The trial investigates the use of various early brain damage scoring systems in adult patients admitted to intensive care units after experiencing cardiac arrest. Cardiac arrest patients often face poor outcomes despite successful return of spontaneous circulation, and doctors use several scores to predict prognosis and guide post-resuscitation care. This study aims to compare and externally validate these scoring methods to identify the most effective tool for treatment decisions and communication with patient relatives. Participants will have early prognosis scores calculated at intensive care unit admission, typically within about three hours after the cardiac arrest event. These scores are based on clinical and biological values and are assessed without altering standard care, as this is an observational study focused on diagnostic evaluation. The study does not involve experimental treatments but observes and compares existing scoring methods. During the study, participants will be monitored through their intensive care admission, where data relevant to the scoring systems will be collected. Researchers will measure the accuracy of the Cerebral Admission Hospital Prognosis CAHP Score and other scores by determining their predictive value for patient outcomes. The study spans several years, with the primary outcome measured at ICU admission and the overall study completion expected by the end of 2027.

Age: 18Years +All Genders
5 locations
E

Actively Recruiting

Researchers are studying adults with bronchiectasis who have recently developed an airway infection with Pseudomonas aeruginosa PA. The study compares two antibiotic treatments to see which is better at clearing the infection. This is a Phase 2 randomized trial aiming to provide clearer evidence on treatment options, as current guidelines offer different antibiotic regimens without a clear favorite, affecting patients quality of life and healthcare costs. Participants are randomly assigned to one of two antibiotic treatments over a three-month period. One group receives oral fluoroquinolone combined with nebulized colistimethate, while the other group receives intravenous beta-lactam antibiotic plus oral fluoroquinolone and nebulized colistimethate. After the initial two-week intensive phase, both groups continue nebulized colistimethate alone for 2.5 months. Following treatment, participants are monitored for an additional nine months, making the total study period 12 months. During the study, participants undergo regular assessments including respiratory sample tests to check for PA eradication, questionnaires on quality of life and treatment burden, and monitoring for adverse events. Researchers will measure PA eradication rate at 6 months as the primary outcome. Secondary outcomes include time to first exacerbation, exacerbation rates at various intervals, detection of antibiotic resistance, and health economic evaluations. The study involves several follow-up visits over one year to track these outcomes and participant well-being.

Age: 18Years +All GendersPhase 2
18 locations
S

Actively Recruiting

Researchers are studying adolescents and young adults with severe haemophilia to understand how well they stick to their healthcare routines as they transition from adolescence to adulthood. This study builds on a previous cross-sectional study called TRANSHEMO, which found that young adults tend to have lower adherence to healthcare management than adolescents. The new study, TRANSHEMO 2, uses a longitudinal design to better identify factors that influence sustained adherence over time during this important life transition. Participants are young adults aged 20 to 29 years who have severe haemophilia and previously took part in the TRANSHEMO project as adolescents. The study involves completing questionnaires to collect information on healthcare adherence and related factors. This observational study does not involve treatment interventions but focuses on gathering data to compare adherence before and after transition to adult care. During the study, researchers will collect data on the number of follow-up visits, adherence to clinical follow-up and treatment, number of haemorrhagic events, and other health-related outcomes using registry information and participant reports. Additional analyses will explore quality of life, coping strategies, autonomy, and family functioning. The study aims to last until June 2027, with primary outcome data collected around December 2026, providing insights into how adherence changes and what influences it during the transition to adulthood.

Age: 20Years - 29YearsAll Genders
25 locations
N

Actively Recruiting

Developmental and Epileptic Encephalopathies DEE are a diverse group of neurodevelopmental disorders associated with epilepsy and their underlying causes. Researchers aim to create a large national database with retrospective follow-up of many patients to better understand specific biomarkers. This will help improve classification and knowledge of DEEs natural progression depending on their causes, allowing for more personalized care and development of management recommendations where none currently exist. This observational study includes patients diagnosed with DEE and control patients undergoing routine EEG exams without epilepsy diagnoses. Data from 2002 to 2026 will be reused to identify diagnostic and early predictive biomarkers, categorize patient subgroups with these biomarkers, and assess quality of life, adaptive behavior, behavioral disorders, and autism spectrum disorders. The study uses existing clinical data without administering new treatments. Participants data will be analyzed retrospectively to find markers linked to neurodevelopmental outcomes in DEE. The study will assess multiple aspects of patients lives and behaviors over time. No new interventions or visits are required, as the study relies on existing health records. The trial runs until the end of 2026, with the goal to improve understanding and personalized management of DEE.

All AgesAll Genders
23 locations
P

Actively Recruiting

Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.

Age: 18Years - 69YearsAll GendersPhase 3
69 locations

1-10 of 27

1